Ballouz, Sara
Kawaguchi, Risa Karakida http://orcid.org/0000-0003-1764-5721
Pena, Maria T.
Fischer, Stephan http://orcid.org/0000-0002-7034-4103
Crow, Megan
French, Leon http://orcid.org/0000-0002-9409-4583
Knight, Frank M.
Adams, Linda B. http://orcid.org/0000-0001-6265-3531
Gillis, Jesse http://orcid.org/0000-0002-0936-9774
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (R01LM012736)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH113005)
Article History
Received: 6 January 2022
Accepted: 30 October 2023
First Online: 9 November 2023
Competing interests
: L.F. owns shares in and has received consulting fees from Quince Therapeutics (formerly Cortexyme Inc.). L.F. has additionally received consulting fees from PeopleBio Co., Keystone Bio, and a separate undisclosed company, for which confidentiality agreements prevent disclosure, and these arrangements are entirely independent of this work. The remaining authors report no competing interests.